TD Cowen analyst Ritu Baral reiterated a Buy rating on Ovid Therapeutics Inc (NASDAQ: OVID).The analyst commented, "OVID reported encouraging ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE